# LRIG3

Source: https://onco.cc/targets/lrig3/  
OnCo record `lrig3` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

LRIG3 (Leucine-rich repeats and immunoglobulin-like domains protein 3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer, Lung cancer and Non-small-cell lung cancer.

## Summary

May play a role in craniofacial and inner ear morphogenesis during embryonic development. May act within the otic vesicle epithelium to control formation of the lateral semicircular canal in the inner ear, possibly by restricting the expression of NTN1.

Open Targets scores its association with cancer at 0.63 (direct and indirect evidence; datatypes literature 0.91, genetic association 0.03, somatic mutation 0.82). IntOGen calls it a driver in 1 cohort (0 activating, 1 loss-of-function), covering Bladder Urothelial Carcinoma.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: leucine rich repeats and immunoglobulin like domains 3; Leucine-rich repeats and immunoglobulin-like domains protein 3; FLJ90440; KIAA3016
- Tags: cancer-genes-wave
- Symbol: LRIG3
- Class: tumor-suppressor
- Biology: May play a role in craniofacial and inner ear morphogenesis during embryonic development. May act within the otic vesicle epithelium to control formation of the lateral semicircular canal in the inner ear, possibly by restricting the expression of NTN1. Location: Cell membrane; Cytoplasmic vesicle membrane (UniProt). Locus 12q14.1 (HGNC).
- Where found: Bladder & urothelial cancer: IntOGen driver in 1 cohort (BLCA); Lung cancer: Open Targets association 0.55 with lung cancer (MONDO_0008903); Non-small-cell lung cancer: Open Targets association 0.53 with non-small cell lung carcinoma (MONDO_0005233)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it a loss-of-function (LoF) driver in 1 cohort. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:30991: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:30991
- UniProt Q6UXM1: https://www.uniprot.org/uniprotkb/Q6UXM1/entry
- NCBI Gene 121227: https://www.ncbi.nlm.nih.gov/gene/121227
- Ensembl ENSG00000139263: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000139263

## Connected records

- collections: [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)

---
JSON: https://onco.cc/api/v1/entities/lrig3.json